Experimental Dual-Target CAR t therapy takes on Hard-to-Treat blood cancers
Disease control
Recruiting now
This early-phase study tests a new type of cell therapy (BCMA-CD19 cCAR) in 12 people with multiple myeloma or plasmacytoid lymphoma that has returned or not responded to standard treatments. The main goal is to see if the therapy is safe and tolerable. Participants receive a sin…
Phase: PHASE1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC